drugset / Trial / NCT02290431
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of panobinostat in combination with bortezomib and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2014-12-16
- Primary completion
- 2017-12-29
- Completion
- 2018-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Panobinostat | Small molecule | 20 mg | Oral |